The data demonstrate that the addition of mimic‐5107 or EPO‐EVs effectively targets EGFR and further enhances RhoA activity, thereby alleviating inflammatory bone loss in LPS‐induced mBMSCs and promoting alveolar bone development in periodontitis mouse models. Here, EPO is linked to periodontitis.